Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 9/20 | 0.55 |
| ▸ | PRSS1 | P07477 | 9/20 | 0.55 |
| ▸ | F7 | P08709 | 9/20 | 0.55 |
| ▸ | F10 | P00742 | 8/20 | 0.55 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.51 |
| ▸ | F3 | P13726 | 2/20 | 0.51 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.51 |
| ▸ | MRGPRX1 | Q96LB2 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6777370 | 0.92 | F7 (0.50) | F2PRSS1F7F10PRSS2 | |
| SCHEMBL6780280 | 0.89 | LMNA (0.47) | F2PRSS1F7F10TSHR | |
| SCHEMBL6779135 | 0.88 | TSHR (0.44) | F2PRSS1F7F10TSHR | |
| SCHEMBL6779349 | 0.87 | TSHR (0.48) | F2TSHRALDH1A1MAPTKDM4E | |
| SCHEMBL6778082 | 0.87 | F10 (0.42) | F2PRSS1F7F10PRSS2 | |
| SCHEMBL6780268 | 0.87 | F10 (0.46) | F2PRSS1F10TSHRALDH1A1 | |
| SCHEMBL6779185 | 0.86 | MEN1 (0.47) | F2PRSS1F7F10TSHR | |
| SCHEMBL6779801 | 0.86 | F10 (0.43) | F2PRSS1F7F10TSHR | |
| SCHEMBL6777481 | 0.81 | ITGB3 (0.41) | F2PRSS1F7F10ALDH1A1 | |
| SCHEMBL6777979 | 0.81 | KDM4E (0.44) | F2TSHRALDH1A1MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6794507-B2 | Compounds that inhibit factor Xa activity | MORPHOCHEM AG (DE) | 2004-09-21 | — | — | US | disclosed |
| US-20030153510-A1 | Novel compounds inhibiting factor xa activity | CAPPI MICHAEL W (DE) | 2003-08-14 | — | — | US | disclosed |
| EP-1311473-A2 | NOVEL COMPOUNDS INHIBITING FACTOR XA ACTIVITY | Morphochem AG (DE) | 2003-05-21 | — | — | EP | disclosed |
| WO-2002016312-A2 | NOVEL COMPOUNDS INHIBITING FACTOR XA ACTIVITY | MORPHOCHEM AG (DE) | 2002-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030153510-A1 | Novel compounds inhibiting factor xa activity | SERPINC1, F11, TFPI | F2 7/4885PRSS1 51/4885F7 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.